What is Polyplus?
Polyplus stands as a premier upstream solutions provider, specializing in the intricate production of advanced biologic and cell and gene therapies. The company offers a comprehensive suite of transfection reagents, kits, and essential support services designed to optimize nucleic acid delivery, plasmid engineering, and protein manufacturing. Catering to both research and commercial-scale operations, Polyplus empowers life sciences clients by enhancing process economics while rigorously adhering to scientific and regulatory mandates. Their global footprint and dedication to accelerating therapeutic development position them as a key enabler for groundbreaking nucleic acid-based therapies.
How much funding has Polyplus raised?
Polyplus has raised a total of $3.4M across 1 funding round:
Unspecified
$3.4M
Unspecified (2011): $3.4M, investors not publicly disclosed
What's next for Polyplus?
With the backing of major enterprise-level funding, Polyplus is poised for accelerated growth and enhanced market penetration. The recent capital infusion is anticipated to drive the scaling of their innovative production solutions, potentially expanding their service offerings and solidifying their position in the competitive biopharmaceutical landscape. Future strategic initiatives may involve further research and development into next-generation delivery systems and increased global outreach to support the burgeoning demand for advanced cell and gene therapies.
See full Polyplus company page
